Spyre Therapeutics (SYRE) Expected to Post Quarterly Earnings on Tuesday

Spyre Therapeutics (NASDAQ:SYRE) is expected to be releasing its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Spyre Therapeutics to announce earnings of ($0.71) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 9:30 AM ET.

Spyre Therapeutics (NASDAQ:SYRE) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.08). On average, analysts expect Spyre Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Spyre Therapeutics Stock Performance

Spyre Therapeutics stock opened at $96.50 on Tuesday. Spyre Therapeutics has a fifty-two week low of $14.51 and a fifty-two week high of $105.09. The company has a market capitalization of $8.49 billion, a price-to-earnings ratio of -46.22 and a beta of 3.02. The stock has a fifty day moving average of $86.02 and a two-hundred day moving average of $61.28.

Insiders Place Their Bets

In other news, Director Michael Thomas Henderson sold 80,000 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $74.40, for a total transaction of $5,952,000.00. Following the sale, the director owned 88,606 shares in the company, valued at $6,592,286.40. This trade represents a 47.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott L. Burrows sold 15,000 shares of Spyre Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $87.13, for a total value of $1,306,950.00. Following the completion of the sale, the chief financial officer directly owned 97,994 shares of the company’s stock, valued at approximately $8,538,217.22. This represents a 13.28% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 282,500 shares of company stock worth $21,741,101. 15.69% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Persistent Asset Partners Ltd purchased a new position in shares of Spyre Therapeutics during the 4th quarter worth about $74,000. Russell Investments Group Ltd. grew its holdings in Spyre Therapeutics by 2,881.7% in the third quarter. Russell Investments Group Ltd. now owns 4,234 shares of the company’s stock valued at $71,000 after purchasing an additional 4,092 shares during the period. Tower Research Capital LLC TRC increased its position in Spyre Therapeutics by 182.2% during the second quarter. Tower Research Capital LLC TRC now owns 5,769 shares of the company’s stock worth $86,000 after purchasing an additional 3,725 shares during the last quarter. Martingale Asset Management L P purchased a new position in Spyre Therapeutics during the fourth quarter worth approximately $227,000. Finally, Virtus Investment Advisers LLC raised its stake in Spyre Therapeutics by 23.2% during the fourth quarter. Virtus Investment Advisers LLC now owns 7,913 shares of the company’s stock worth $259,000 after purchasing an additional 1,488 shares during the period. Institutional investors and hedge funds own 80.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on SYRE shares. Wells Fargo & Company increased their price objective on Spyre Therapeutics from $50.00 to $90.00 and gave the company an “overweight” rating in a research note on Tuesday, April 14th. JonesTrading boosted their target price on shares of Spyre Therapeutics from $64.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, April 17th. Wall Street Zen lowered shares of Spyre Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, April 26th. Wolfe Research cut shares of Spyre Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Tuesday. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on shares of Spyre Therapeutics from $115.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, June 23rd. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Spyre Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $101.42.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.